Journal
JOURNAL OF NERVOUS AND MENTAL DISEASE
Volume 202, Issue 7, Pages 513-520Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/NMD.0000000000000113
Keywords
LSD; psychedelic; psycholytic therapy; hallucinogen; anxiety disorder
Categories
Funding
- Schweizerische Aerztegesellschaft fur Psycholytische Therapie (Swiss Medical Society for Psycholytic Therapy)
- Multidisciplinary Association for Psychedelic Studies
- MAPS
Ask authors/readers for more resources
A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases. Treatment included drug-free psychotherapy sessions supplemented by two LSD-assisted psychotherapy sessions 2 to 3 weeks apart. The participants received either 200 mu g of LSD (n = 8) or 20 Kg of LSD with an open-label crossover to 200 mu g of LSD after the initial blinded treatment was unmasked (n = 4). At the 2-month follow-up, positive trends were found via the State-Trait Anxiety Inventory (STAI) in reductions in trait anxiety (p = 0.033) with an effect size of 1.1, and state anxiety was significantly reduced (p = 0.021) with an effect size of 1.2, with no acute or chronic adverse effects persisting beyond 1 day after treatment or treatment-related serious adverse events. STAI reductions were sustained for 12 months. These results indicate that when administered safely in a methodologically rigorous medically supervised psychotherapeutic setting, LSD can reduce anxiety, suggesting that larger controlled studies are warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available